The Michigan Medicine Scleroderma Program, established in 2004 in the Division of Rheumatology, is a multidisciplinary group of caregivers, scientists, and clinical researchers dedicated to advancing research and improving care for patients with scleroderma and related conditions.
Mission and Goals
The mission of the Scleroderma Program is to provide local, national, and international leadership in advancing the treatment of scleroderma and related conditions, through excellence in clinical care, teaching, and research.
Our goals are to develop effective therapies for scleroderma and its complications, and to research the causes and mechanisms of disease. It is only through enhanced understanding of the disease process that a cure will be possible.
- Clinical care with emphasis on cost-effective outpatient management
- Outreach to the community of patients and physicians
- Research into the cause, mechanisms, and treatment
- Education of physicians and allied health professionals
Scleroderma is an inherently complex disease which is best addressed by a multidisciplinary team approach to treatment and research. The University of Michigan Medical School is one of the leading research institutions in the world. Its clinical and scientific assets are extensive, cutting edge, and uniquely suited to the needs of the scleroderma community.
Faculty from many disciplines, including Pulmonary Medicine, Cardiology, Gastroenterology, Infectious Diseases, Pediatric Rheumatology, Dermatology, Hand Surgery, Physical Medicine & Rehabilitation, and the Rogel Cancer Center participate in program activities. Meet the team.
Our faculty are continuously involved in complex trials that are designed to improve the quality of life and extend survival. Crucial to this enterprise is refined investigation of the science of outcome measures, which in turn, leads to more robustly designed clinical trials for the future. An effective and talented team has been assembled and a broad portfolio of research is in progress. Learn more.
Increasing focus is on initiatives in research into the cause and pathobiology of scleroderma. Basic scientists are active at Michigan Medicine in areas of direct relevance to scleroderma including the biology of fibrosis, vascular biology, and basic cellular immunology.
The ScleroLab, housed in the Division of Rheumatology, is led by John Varga, MD, Associate Director of the Scleroderma Program. Dr. Varga and his team focus on defining the cellular and molecular mechanisms and genetic factors of fibrosis associated with scleroderma with the goal of developing novel targets for diagnosis, precision medicine, and targeted therapies.
The Scleroderma Program provides clinical care, primarily on a consultative basis to patients from Michigan and the Midwest, but also serves as an international referral center. Learn more.